Attached herewith the press release of unaudited financial results for the quarter and nine months ended 31st December, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Veerhealth Care Ltd reported strong Q3 FY26 results with Total Income of ₹6.96 crore, up 73.13% year-on-year, and Net Profit (PAT) of ₹0.40 crore, up 474.18% YoY. EBITDA grew 181.44% YoY to ₹0.94 crore, with EBITDA margin expanding 490 basis points to 13.36%, and Net Profit margin improving 408 bps to 5.81%. The company highlighted that it received US FDA clearance, enabling exports of OTC drug products to the USA, and is also pursuing USFDA approval for medical device category products. Management expects US tariff reductions and the India-EU Trade Deal 2026 to boost export growth, and is in talks with a major Russian group for oral care exports. The company also onboarded its Ayuveer brand on Myntra (now on Amazon, Flipkart, and Myntra) and began production at a new facility with in-house plastic moulding for packaging. Forward guidance includes FY27 revenue of ₹45–50 crore with 7–10% PAT margin, and a target of ₹100 crore revenue with 10% PAT margin within 24 months.
Strong top-line and bottom-line growth, combined with US FDA clearance and new export opportunities (USA, EU, Russia), supports a positive growth outlook. However, the absolute PAT remains small and forward-looking targets are ambitious, so investors should weigh the strong momentum against the company's small scale.